Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of vismodegib in advanced basal cell carcinoma
NL-OMON39484Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vismodegib in basal cell carcinoma (BCC), sponsored by Roche. Primary endpoint: Safety. Started Jul 2012; status: active, not recruiting.
02
Drugs
vismodegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NL-OMON39484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39484.